A randomized phase II study for tertiary prevention of squamocellular cancer of head and neck (SCCHN) with a dietary intervention
Federica Favales(Istituti di Ricovero e Cura a Carattere Scientifico), Paolo Bossi(Humanitas University), Roberta Granata(Istituti di Ricovero e Cura a Carattere Scientifico), Lisa Licitra(University of Milan), Chiara Villa(Centre National de la Recherche Scientifique), P Pistillo(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
|Cancer|2020|1.3k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study
|European Journal of Cancer|2015|486